Plain-English translation of NCT07185243 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new treatment called hV01, which is a modified virus designed to fight cancer by being injected directly into tumors. In the first part of the study, doctors will test whether hV01 alone is safe and well-tolerated. In the second part, they will combine hV01 with tislelizumab, a medication that helps your immune system recognize and attack cancer cells.
Standard cancer treatments don't work for everyone, and some cancers become resistant to them. This study is exploring whether combining a virus-based therapy with an immune-boosting drug might offer a new option for people with advanced solid tumors that have stopped responding to conventional treatments.
You likely qualify if…
You likely don't qualify if…
The study has two parts. In Part A, you will receive injections of the virus-based treatment directly into a tumor either twice or three times within each 28-day cycle, and doctors will monitor you closely for any side effects. If Part A shows the treatment is safe, Part B will involve receiving the same injections followed by infusions of the immune-boosting medication given through an IV on specific days within each 42-day cycle. Throughout the study, you will have regular blood tests and imaging scans to check how your tumors are responding to the treatment.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
China
Sponsor
Hangzhou Converd Co., Ltd.
Collaborators
Xiamen Humanity Hospital
Enrollment target
~24 participants
Started
June 2025
Primary completion
June 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jun Qiu
Xiamen Humanity Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.